New strategies to overcome the drawbacks of currently available flu vaccines

Advances in Experimental Medicine and Biology

Volumn 655, Issue , 2009, Pages 243-252

  Fichera, Epifanio ^a   Felnerova, Diana ^b   Mischler, Robert ^b   Viret, Jean François ^b   Glueck, Reinhard ^b  

^a Etna Biotech Srl   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIVE VACCINE; SUBUNIT VACCINE; VIRUS HEMAGGLUTININ; VIRUS PROTEIN;

ARTICLE; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPOTENTIATION; INFECTION PREVENTION; INFLAMMATION; INFLUENZA; MUCOSAL DISEASE; NONHUMAN; PRIORITY JOURNAL; SORE THROAT; VACCINE PRODUCTION; ANIMAL; EPIDEMIC; GENETICS; IMMUNE SYSTEM; INFECTION CONTROL; METHODOLOGY; PREVENTIVE HEALTH SERVICE; REVIEW; VACCINATION;

AVES; FLU VACCINE;

ANIMALS; COMMUNICABLE DISEASE CONTROL; DISEASE OUTBREAKS; EPITOPES; HUMANS; IMMUNE SYSTEM; IMMUNIZATION PROGRAMS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINATION;

EID: 77955482097     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1132-2_15     Document Type: Article

References (57)

1. Lamb RA. Krug RM. Orthomyxoviridae: The viruses and their replication. In: Fields BN, Knipe DM, Howly PM, eds, Fields Virology. Philadelphia: Lippincott-Raven Publishers. 1996:1353-1395.
2. The Universal Virus Database ICTVdB: http ://www.ncbi.nlm.nih.gov/ICTVdb/ Ictv/index.htm
3. Nicholson KG. Human influenza. In: Nicholson KG. Webster RG. Hay AJ, eds, Textbook of Influenza. Oxford: Blackwell Science; 1998:219-264
4. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003; (362):1733-44.
5. Weekly epidemiological record, 2005; Nr. 33 (80):277-288.
6. Influenza report 2006. edited by Kamps BS, Holfman C and Preisser W, Flying Publisher, 2006.
7. Hemmes JH, Winkler KC, Kool SM. Virus survival as a seasonal factor in influenza and polimyelitis. Nature 1960; (188):430-1.
8. Smith W, Andrewes CH. Laidlaw PP. A virus obtained from influenza patients. Lancet 1933; (1):66-68.
9. Wood JM, Williams MS. History of inactivated influenza vaccines. In: Nicholson KG, Webster RG, Hay AJ eds, Textbook of Influenza. Oxford :Blackwell Science: 1998:317-23.
10. Furminger IGS. Vaccine production. In: Nicholson KG, Webster RG, Hay AJ. eds, Textbook of Influenza Oxford:Blackwell Science Ltd: 1998:324-332.
11. www.medimmune.com
12. Medema J, Wijnands DT, Palache AM. The role of MDCK-based influenza vaccine Influvac TC in inter(pandemics). International Congress Series 2004; 1263:822-825.
13. Ozaki H, Govorkova EA, Li C et al. Generation of high-yielding influenza A viruses in Mrican green monkey kidney (Vero) cells by reverse genetics. J Virol 2004; 78(4):1851 -7. (Pubitemid 38176716)
14. Pau MG, Ophorst C, Koldijk MH et al. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 2001; 19(17-19):2716-21. (Pubitemid 32234294)
15. www.clinicaltrials.gov
16. Wang D, Christopher ME, Nagata LP et al. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses. J Clin Virol 2004; 31(Suppl1):S99-106. (Pubitemid 39574715)
17. Tamura S. Tanimoto T. Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 2005; 58(4) :195-207. (Pubitemid 41460922)
18. Brett IC ,Johansson BE. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 2005; 339(2) :273-80. (Pubitemid 41169794)
19. Van Kampen KR, Shi Z, Gao P et al. Safety and immunogenicity of adenovirus-vectored nasal and epicuraneous influenza vaccines in humans. Vaccine 2005; 23(8):1029-36. (Pubitemid 40037652)
20. Cassetti MC, Katz JM. Wood J. Report of a consultation on role of immunological assays to evaluate efficacy of influenza vaccines, Initiative for Vaccine Research and Global Influenza Programme, World Health Organization, Geneva, Switzerland, 2005. Vaccine 2006; 24(5) :541-3. (Pubitemid 43017818)
21. Nichol KL. Efficacy/clinical effectiveness of inactivated influenza virus vaccines in adults. In: Nicholson KG, Webster RG, Hay AJ. eds, Textbook of Influenza. Oxford :Blackwell Science Ltd: 1998:358-372.
22. McElhaney JE, Xie D, Hager WD et al. T-cell responses are better correlates of vaccine protection in the elderly.J ImmunoL 2006; 176(10) :6333-9.
23. Belshe RB, Couch RB, Glezen WP et al. Live attenuated intranasal influenza vaccine. Vaccine 2002; 20(29 -30):3429-30.
24. Thomas PG, Keatinll R, Hulse-Post DJ et al. Cell-mediated protect ion in influenza infection. Emerg Infect Dis 2006; 12(1):48-54. (Pubitemid 43143535)
25. Bresson JL, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367(9523) :1657-64. (Pubitemid 43744370)
26. Gupta RK, Relyved ER, Lindblad EB et al. Adjuvants-a balance between toxicity and adjuvanticity. Vaccine 1993; 11(3) 293-306.
27. Gliick R, Mischler R, Finkel BF et al. Immunogenicity of new virosome influenza vaccine in the elderly people. Lancet 1994; (344):160-163. (Pubitemid 24218879)
28. Stephenson I, Bugarini R. Nicholson KG et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/ Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005; 191(8):1210-5.
29. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003; 49(3) :177-84. (Pubitemid 36438758)
30. Moser C, Metcalfe IC. Viret JF. Virosomal adjuvanted antigen delivery systems. Expert Rev Vaccines 2003; 2(2) :189-96 (Pubitemid 36559924)
31. Review. Erratum in: Expert Rev Vaccines 2003; 2(6) :842.
32. Takeshita F, Tanaka T. Matsuda T et al. Toll-Like Receptor Adaptor Molecules Enhance DNA-Raised Adaptive Immune Responses against Influenza and Tumors through Activation of Innate Immunity. J Viro1 2006; 80(13):6218-24. (Pubitemid 43927424)
33. Guillot L, Le Goffic R, Bloch S et al. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 2005; 280(7) :5571-80. (Pubitemid 40280035)
34. Lund JM, Alexopoulou L, Saro A et al. Recognition of single-stranded RNA viruses by Toll-like receptor. Proc Nad Acad Sci USA 2004; 101(15):5598-5603. (Pubitemid 38481202)
35. Treanor J, Nolan C, O'Brien D et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 2006: 24(3):254-62. (Pubitemid 41790428)
36. Stephenson I, Zambon MC, Rudin A et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 2006; 80(10):4962-70.
37. Eriksson AM, Schon KM, Lycke NY. The cholera toxin-derived CTAI-DD vaccine adjuvant administered intranasally docs not cause inflammation or accumulate in the nervous tissues. J Immunol 2004: 173(5) :3310-9. (Pubitemid 39142040)
38. Helgeby A, Robson NC, Donachie AM et al. The combined CTAI-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B-cells. J Immunol 2006; 176(6):3697-706. (Pubitemid 43364016)
39. + CTL inefficiendy alter incubation with viral protein together with ISCOMATRIX. Vaccine 2004; 22(21-22) :2769-75. (Pubitemid 38900653)
40. Coulter A, Harris R. Davis R et al. Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Vaccine 2003; 21(9-10):946-9. (Pubitemid 36126429)
41. Ennis FA, Cruz J. Jameson J et al. Augmentation ofhuman influenza A virus-specific cytotoxic T-Iymphoeyre memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 1999: 259(2) :256-61. (Pubitemid 29393375)
42. Borsutzky S, Kretschmer K. Becker PD et al The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B-lymphocytes via the TLR2 without the need of accessory cells. J Immunol 2005: 174(10):6308-13. (Pubitemid 40663823)
43. Muszkat M, Greenbaum E, Ben-Yehuda A et al. Local and systemic immune response in nursinghome elderly following intranasal or intramuscular immunization with inactivated influenza vaccine. Vaccine 2003: (21):1180-1186. (Pubitemid 36139947)
44. Glück U. Gebbers J-O , Glück R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J Virol 1999; 73(9) :7780-7786. (Pubitemid 29383262)
45. http://www.medletter.com/freedocs/flumist.pdf
46. Epstein SL. Control of influenza virus infection by immunity to conserved viral features. Expert Rev Anti Infect Ther 2003; 1(4):627-38.
47. Deroo T. Jou WM, Piers W, Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine 1996; 14(6):561-9. (Pubitemid 26173757)
48. Epstein SL, Misplon JA, Lawson CM et al. Beta 2-microglobulin-deficient mice can beprotected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase. J Immunol 1993; 150(12):5484-93. (Pubitemid 23180662)
49. Gianfrani C, Oseroff C, Sidney J et al. Human memory CTL response specific for influenza A virus is broad and mulcispecific, Hum Immunol 2000: 61(5):438-52. (Pubitemid 30238274)
50. Cox MM. Cell-based protein vaccines for influenza. Curr Opin Mol Ther 2005; 7(1) :24-9. (Pubitemid 40287452)
51. Thomas PG, Keating R. Hulse-Post DJ et al, Cell-mediated protection in influenza infection. Emerg Infect Dis 2006: 12(1):48-54. (Pubitemid 43143535)
52. + T-cell populations. Nat Immunol 2005: 6(4) :382-9. (Pubitemid 41716778)
53. Kedzierska K. Turner SJ. Doherty PC . Conserved T-cell receptor usage in primary and recall responses to an immunodominant influenza virus nucleoprotein epitope. Proc Nad Acad Sci USA 2004: 101(14) :4942-7. (Pubitemid 38469182)
54. Fan J, Liang X, Horton MS et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets and rhesus monkeys. Vaccine 2004: 22(23-24) :2993-3003. (Pubitemid 39037199)
55. Jegerlehner A. Schmitz N, Storni T et al. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.J Immunol 2004; 172(9):5598-605. (Pubitemid 38542062)
56. Ozaki T, Yauchi M. Xin KQ et al. Cross-reactive protection against influenza A virus by a topically applied DNA vaccine encoding M gene with adjuvant. Viral Immunol 2005: 18(2):373-80. (Pubitemid 41106016)
57. Falcon AM, Fernandez-Sesma A, Nakaya Y et al. Attenuation and immunogenicity in mice of temperature-sensitive influenza viruses expressing truncated NS1 proteins. J Gen Virol 2005: 86(Pt 10):2817-21. (Pubitemid 41410473)